{"filings":[{"id":2133476,"accession_number":"0001410098-26-000044","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-08-07T20:18:31+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix derivative suit settlement preliminarily approved; final hearing Sept 23, 2026","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court granted preliminary approval on July 24, 2026; final settlement hearing set for Sept 23, 2026 in Newark, NJ.","Settlement requires corporate governance reforms maintained for 3.5 years; no monetary payment to stockholders.","Plaintiffs' counsel may seek up to $3.9M in fees; defendants reserve right to oppose.","Claims alleged fiduciary breaches over DefenCath manufacturing deficiencies and delayed FDA approval (2019-2022).","Settlement resolves federal and state derivative actions; securities class action not part of this settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1416003,"accession_number":"0001410098-26-000040","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-07-02T20:30:35+00:00","items":["8.01"],"status":"ready","headline":"CorMedix appoints Elizabeth Hurlburt as Chief Operating and Commercial Officer; Michael Seckler departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elizabeth Hurlburt, previously COO, appointed to newly created role of Chief Operating and Commercial Officer, effective June 29, 2026.","Hurlburt will oversee commercial, medical affairs, regulatory, and clinical functions, reporting to Chairman & CEO Joseph Todisco.","Michael Seckler has left the Company as part of the leadership restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1369796,"accession_number":"0001410098-26-000037","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-07-01T11:14:07+00:00","items":["4.01"],"status":"ready","headline":"CorMedix dismisses CBIZ CPAs, appoints EY as auditor; cites material weakness in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed CBIZ CPAs on June 25, 2026, and appointed Ernst & Young as new independent auditor for FY 2026.","CBIZ CPAs' report on FY 2025 financials was unqualified; no disagreements on accounting principles.","A material weakness in internal control over financial reporting was identified (operational effectiveness of review of non-routine transactions).","The material weakness was previously reported in the 2025 10-K filed March 5, 2026.","CBIZ CPAs provided a letter dated July 1, 2026, agreeing with the statements in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1250365,"accession_number":"0001410098-26-000028","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-06-24T20:30:10+00:00","items":["5.07"],"status":"ready","headline":"CorMedix shareholders reject five of eight proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with over 33M votes each; broker non-votes ~20M.","Advisory say-on-pay and auditor ratification approved with ~73% and 97% of votes cast respectively.","Proposal to ratify COD Amendments (Proposal 4) not approved: 37.3M for, 3.2M against, plus 20M broker non-votes.","Proposals 5-8 (charter amendments, class voting, exclusive forum, officer liability) all failed to pass.","Management's proposed governance changes were largely rejected by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900958,"accession_number":"0001213900-26-066061","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-06-08T12:45:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Federal Circuit upholds CorMedix's MINOCIN patents; Nexus generic barred from market","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Federal Circuit affirmed district court: Nexus generic minocycline infringes two CorMedix patents, invalidity rejected.","Permanent injunction upheld barring Nexus from marketing generic before patent expiration.","Patents are FDA Orange Book listed covering MINOCIN for Injection, used for serious infections.","CEO Joseph Todisco: ruling validates strength of MINOCIN IP portfolio and protects innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77724,"accession_number":"0001410098-26-000020","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-05-14T11:34:46+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.","DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.","Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.","Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.","Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92687,"accession_number":"0001213900-26-047748","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.","Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.","Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.","CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.","Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103718,"accession_number":"0001213900-26-024777","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.","FY2026 guidance: revenue $300M-$320M, adjusted EBITDA $100M-$125M, DefenCath sales $150M-$170M.","Q4 2025 net revenue $129M, DefenCath sales $91M; FY2025 pro forma net revenue $401M.","Pipeline milestones: REZZAYO prophylaxis Ph3 data expected Q2 2026; DefenCath TPN (NUTRI-LOCK) data 1H 2027.","Balance sheet at Dec 31 2025: cash & short-term investments $149M, convertible debt $150M, shares outstanding 79.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103717,"accession_number":"0001213900-26-023881","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.","FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.","Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.","Board approved $75M share repurchase program; cash and short-term investments $148.5M.","Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103716,"accession_number":"0001213900-26-002350","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).","Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.","FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.","CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.","Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10."],"consensus_eps_estimate":0.8325,"consensus_eps_actual":2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":311709000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119976,"accession_number":"0001213900-25-108716","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.","FY 2025 pro forma net revenue guidance raised to $390-410M; Q4 guidance $115-135M; adjusted EBITDA guidance $220-240M.","One-time $59.7M tax benefit from NOL carryforwards realization contributed to net income.","Melinta acquisition closed Aug 29; integration ahead of schedule with ~$30M annual synergy run-rate expected by end 2025.","Cash and short-term investments $55.7M at Sept 30; projecting year-end ~$100M; Phase III ReSPECT enrollment completed."],"consensus_eps_estimate":0.6581,"consensus_eps_actual":1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":183093736.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119975,"accession_number":"0001213900-25-100156","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.","FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.","Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.","Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.","Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M."],"consensus_eps_estimate":0.6581,"consensus_eps_actual":1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":183093736.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136546,"accession_number":"0001213900-25-093983","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K/A","filed_at":"2025-09-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.","Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.","CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136549,"accession_number":"0001213900-25-082956","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.","Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.","Transaction expected near-term accretive to EPS with double-digit accretion in 2026.","Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.","Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136548,"accession_number":"0001213900-25-075010","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CorMedix closes $150M convertible note offering due 2030 at 4.00% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $150M aggregate principal of 4.00% Convertible Senior Notes due 2030 in a private placement.","Initial conversion rate: 74.2515 shares per $1,000 principal (implied conversion price ~$13.47/share).","Notes issued under indenture with U.S. Bank Trust Company; proceeds not specified but likely for corporate purposes.","Sale exempt from registration under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136547,"accession_number":"0001213900-25-072814","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.","Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.","Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.","Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.","Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153735,"accession_number":"0001213900-25-059702","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix closes $85M public offering of common stock, net proceeds $82.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 6,604,507 shares at gross proceeds ~$85M.","Net proceeds ~$82.2M; could reach ~$94.8M if underwriters' option exercised in full.","Underwriters have a 30-day option to purchase up to 990,676 additional shares.","Proceeds to be used for general corporate purposes, including R&D and strategic transactions.","RBC Capital Markets acted as sole bookrunner; Truist, Citizens, Needham as advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153734,"accession_number":"0001213900-25-057451","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CorMedix shareholders elect all 7 director nominees, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Dillione 15.6M votes, Duncan 17.6M, Dunton 17.0M, Kaplan 14.2M, Lefkowitz 17.4M, Stewart 15.8M, Todisco 18.3M.","Non-binding say-on-pay passed: 16,086,287 for, 1,999,311 against, 360,596 abstain; 27.6M broker non-votes.","Ratification of CBIZ CPAs as auditor for FY2025 approved: 45,476,764 for, 412,102 against, 156,463 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153733,"accession_number":"0001213900-25-056415","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.","CorMedix amended existing agreement with LDO customer to reflect anticipated increased product use.","Q2 2025 net sales guidance raised from $31M to $35-40M; modest revenue contribution expected in June with growth through H2 2025.","CEO cites implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153732,"accession_number":"0001213900-25-039903","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.","Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.","Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.","Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":39081657.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153731,"accession_number":"0001213900-25-034219","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CorMedix engages CBIZ CPAs as new auditor; Marcum resigns after acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned April 17, 2025; CBIZ CPAs engaged immediately for FY2025, approved by Audit Committee.","No disagreements or reportable events between CorMedix and Marcum during 2023-2024 or through resignation date.","CBIZ CPAs acquired Marcum's attest business effective November 1, 2024; prior auditor continued until April 17, 2025.","Marcum's reports for 2023 and 2024 contained no adverse opinions or modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153730,"accession_number":"0001213900-25-029629","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.","Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.","Cash and short-term investments at March 31, 2025: approx. $77.5M.","Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.","Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":39081657.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172415,"accession_number":"0001013762-25-001844","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.","Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.","Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.","Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.","Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172414,"accession_number":"0001213900-25-001392","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.","Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.","LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.","Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.","FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":43472170.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189414,"accession_number":"0001213900-24-102170","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CorMedix shareholders approve stock plan amendment increasing authorized shares; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan amendment to increase share authorization under 2019 Omnibus Stock Incentive Plan approved with 16.5M FOR, 2.8M AGAINST, 0.8M abstain.","All 7 director nominees elected: Dillione, Duncan, Dunton, Kaplan, Lefkowitz, Stewart, Todisco – each received >15.8M FOR votes.","Non-binding advisory vote on 2023 executive compensation passed (FOR: 17.5M, AGAINST: 2.4M).","Ratification of Marcum LLP as auditor for FY2024 approved with 40.5M FOR, 215K against, 370K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189413,"accession_number":"0001213900-24-091959","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.","Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.","Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.","Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.","Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":12262234.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205914,"accession_number":"0001213900-24-068589","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.","DefenCath net sales $0.8M for partial quarter since April 15 inpatient launch; outpatient QTD sales $5.2M as of Aug 13.","Operating expenses $15.6M in Q2 (+32% YoY) from commercial launch costs; R&D down 86% post-approval.","Cash and short-term investments $45.6M at June 30, sufficient for at least 12 months.","Submitted TPN study protocol to FDA; patient enrollment expected to begin Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":806119.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222935,"accession_number":"0001213900-24-041026","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.","Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.","CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.","Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.","Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242424,"accession_number":"0001213900-24-021573","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.","Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.","FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.","CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.","Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242423,"accession_number":"0001213900-24-008015","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.","List price (WAC) set at $249.99 per 3mL vial; company committed to reduce price if Part B reimbursement is granted.","Reiterates inpatient launch target of April 15, 2024; outpatient launch target of July 1, 2024, contingent on CMS TDAPA approval.","Company will notify CMS to adjust inpatient NTAP reimbursement now that a WAC price is established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259813,"accession_number":"0001213900-23-095909","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CorMedix EVP, General Counsel and Corporate Secretary Phoebe Mounts to depart Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation approved Dec 12, 2023; Mounts ceases as General Counsel and Corporate Secretary immediately, remains EVP through Dec 31.","Termination classified as without cause under Employment Agreement; severance contingent on signing release, cooperation, return of property, and compliance with covenants.","No replacement named; Mounts will assist with transition until Termination Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259812,"accession_number":"0001213900-23-087921","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix announces FDA approval of DefenCath to reduce catheter-related bloodstream infections in hemodialysis patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DefenCath (taurolidine and heparin) is the first FDA-approved antimicrobial catheter lock solution for adult hemodialysis patients.","Phase 3 LOCK-IT-100 trial showed a statistically significant 71% reduction in risk of CRBSIs (Hazard Ratio 0.29).","DefenCath is expected to be available in Q1 2024 in the inpatient setting.","The study enrolled 806 patients and early termination was recommended due to demonstrated efficacy.","CorMedix (CRMD) prepares for commercial launch with healthcare providers and facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259811,"accession_number":"0001213900-23-086937","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q3 net loss $9.7M; FDA inspections complete, launch targeted by Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.7M ($0.17/sh) vs $6.9M ($0.17/sh) in Q3 2022; operating expenses up 50% to $10.5M.","Cash and short-term investments $86.6M as of Sept 30, 2023; sufficient for at least 12 months.","FDA completed preapproval inspections at primary CMO and key suppliers; no known deficiencies.","USPTO issued patent for DefenCath composition-of-matter (expiry April 2042).","Commercial launch targeted before end of Q1 2024 if FDA approval received."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259810,"accession_number":"0001213900-23-081561","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CorMedix shareholders elect 7 directors, approve executive pay, ratify Marcum as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 7 director nominees elected; Robert Stewart received most votes (16.2M for), Janet Dillione fewest (10.6M for).","Non-binding advisory vote on 2022 executive compensation passed: 12.8M for, 4.2M against, 123.5K abstain.","Ratification of Marcum LLP as independent auditor for FY2023 passed: 37.8M for, 700.4K against, 255.2K abstain.","Broker non-votes totaled 21.6M for director elections and compensation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277068,"accession_number":"0001213900-23-068356","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CorMedix board member Paulo F. Costa to retire effective Oct 15, 2023; board size reduced to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paulo F. Costa notified the Board of his retirement, effective October 15, 2023.","Departure is not due to any dispute or disagreement with the Company or its management.","Board will not fill the seat at this time, reducing board size to seven directors.","Company is evaluating how to fill Costa's committee assignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277067,"accession_number":"0001213900-23-064241","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q2 net loss widens to $11.3M; DefenCath NDA PDUFA date Nov 15, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.3M ($0.25 per share) vs $7.6M loss in Q2 2022, driven by increased R&D and SG&A.","Cash and short-term investments $52.4M at June 30; after July equity offering pro forma cash ~$95M.","DefenCath NDA accepted with PDUFA target date of November 15, 2023; CMS set NTAP up to $17,111 if approved.","Operating expenses increased 43% to $11.8M; R&D up 49% to $4.8M; SG&A up 39% to $7.0M.","Strategic initiative with Boston Medical Center to assess CRBSI incidence and health disparities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294962,"accession_number":"0001213900-23-053572","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix prices $40M public offering of 7.5M shares at $4.00/sh and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40M from 7.5M shares at $4.00/sh and 2.5M pre-funded warrants at $3.999.","Underwriters granted 30-day option for up to 1.5M additional shares at $4.00/sh.","Net proceeds ~$37.3M (or ~$43M if option exercised); closing expected July 3, 2023.","Proceeds for general corporate, commercialization efforts, R&D, and working capital.","Offering via shelf S-3; RBC, Truist, JMP as book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294961,"accession_number":"0001213900-23-050240","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix announces FDA acceptance of DefenCath NDA resubmission; PDUFA date Nov 15, 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted DefenCath NDA resubmission as a complete Class 2 response with six-month review.","PDUFA target action date set for November 15, 2023.","DefenCath is a catheter lock solution to reduce bloodstream infections in hemodialysis patients.","CEO Joe Todisco highlighted preparations for potential commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294960,"accession_number":"0001213900-23-040128","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix resubmits DefenCath NDA to FDA for hemodialysis catheter infection prevention","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA for DefenCath resubmitted to FDA as of May 15, 2023; agency acknowledged receipt for processing.","CEO Joe Todisco said resubmission follows prior earnings call; company aims for potential approval in 2023.","DefenCath is designed to reduce bloodstream infections in hemodialysis patients using central venous catheters.","Resubmission addresses prior FDA feedback; no specific timeline for review decision provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294959,"accession_number":"0001213900-23-039770","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 net loss $10.6M; DefenCath NDA resubmitted to FDA for 6-month review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $10.6M ($0.24/share) vs $7.0M loss in Q1 2022; operating expenses $11.0M, up 57% YoY due to pre-launch activities.","DefenCath NDA resubmitted to FDA; classified as Type 2 resubmission with 6-month review cycle, target action date November 2023.","CMS proposed rule grants DefenCath NTAP up to $17,111 per hospital stay, contingent on FDA approval by July 1, 2024.","US Patent Office issued notice of allowance for DefenCath composition, extending IP protection to 2042.","Cash and short-term investments $55.6M; management believes sufficient to fund operations through first half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294958,"accession_number":"0001213900-23-032876","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix to resubmit DefenCath NDA by mid-May; CMS proposes NTAP up to $17,111","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company will resubmit NDA for DefenCath to FDA by mid-May 2023 following Type A meeting.","CMS IPPS 2024 proposed rule includes NTAP of up to $17,111 per hospital stay for DefenCath, conditional on FDA approval before July 1, 2024.","Resubmission uses existing CMO and new heparin API supplier; expects 6-month Class 2 review.","Company plans to add a 3 mL single-dose vial to commercial presentation based on market needs.","NTAP amount based on 75% of WAC price ($1,170 per 3 mL vial) and average 19.5 vials per stay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294957,"accession_number":"0001213900-23-030043","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CorMedix appoints Robert Stewart to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Stewart appointed to Board effective April 13, 2023; Board now has 8 directors, 7 independent.","Stewart is CEO of Theramex; former CEO of Amneal Pharma and COO of Allergan.","Received initial option for 25,000 shares (1/3 vesting at grant, then annually); additional prorated option for 14,200 shares.","Stewart's experience expected to aid CorMedix's transition from development to commercial phase, per CEO.","Press release highlights commercial potential for lead product DefenCath."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315518,"accession_number":"0001213900-23-024301","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).","Cash and short-term investments $58.8M at Dec 31, 2022; $7.2M raised via ATM in Q1 2023.","FDA granted Type A meeting in mid-April to discuss DefenCath NDA resubmission; CMO corrective actions completed.","Agreement with Siegfried AG (Hameln, Germany) as backup CMO for DefenCath manufacturing.","Promoted Erin Mistry to EVP/Chief Commercial Officer and Dr. Tushar Mukherjee to SVP/Head of Technical Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315517,"accession_number":"0001213900-23-016996","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix updates DefenCath NDA resubmission pathways; CMO 1 completes corrective actions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMO 1 completed all corrective actions from FDA's June 2022 inspection; awaits FDA feedback on compliance status.","Heparin API supplier updated DMF; FDA recently approved a supplement referencing same DMF, potentially removing warning letter barrier.","Company plans to submit Type A meeting request by mid-March to seek FDA guidance on CMO 1 clearance and API 1 DMF use.","Pathway #1 (CMO 1 + API 1) could be Class 1 (60-day review); Pathway #2 (CMO 1 + API 2) data expected mid-April, Class 2 (6-month).","Pathway #3 (CMO 2 + API 2) data delayed to Q3 2023; remains backup strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333860,"accession_number":"0001213900-22-070820","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.","Cash and short-term investments $59.0M; sufficient to fund operations through 2023.","CMS increased NTAP reimbursement for DefenCath from $4,387.50 to $14,259.38 per visit.","CMO implemented >95% of FDA corrective actions; NDA resubmission target end of Q1 2023.","R&D expense decreased 51% to $2.3M; SG&A increased 21% to $4.6M on pre-launch activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":35706.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333859,"accession_number":"0001213900-22-065539","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CorMedix dismisses Friedman LLP and appoints Marcum LLP as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Friedman and engagement of Marcum on October 17, 2022.","Friedman's reports for fiscal years 2020 and 2021 contained no adverse opinion or qualification.","No disagreements or reportable events with Friedman occurred during the two most recent fiscal years.","Friedman combined with Marcum effective September 1, 2022; services transferred to Marcum.","Company did not consult with Marcum on accounting principles prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333858,"accession_number":"0001213900-22-064356","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CorMedix stockholders elect directors and approve all four proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven director nominees elected (Costa, Dillione, Duncan, Dunton, Kaplan, Lefkowitz, Todisco) with for votes ranging from 7.6M to 9.2M; 19.1M broker non-votes.","Advisory vote on executive compensation approved: 8,041,682 for, 2,406,462 against, 123,127 abstain.","Amendment and restatement of 2019 Omnibus Stock Incentive Plan approved: 8,110,236 for, 2,308,931 against.","Ratification of Friedman LLP as independent auditor for FY2022 approved: 27,961,029 for, 1,579,888 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351315,"accession_number":"0001213900-22-046610","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix receives second FDA CRL for DefenCath; Q2 net loss $7.6M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second CRL from FDA for DefenCath NDA due to unresolved deficiencies at CMO and heparin supplier.","Entered agreement with Alcami as alternative manufacturer; expects to submit NDA supplement around Q1 2023.","CMS granted conditional NTAP reimbursement, conditioned on FDA approval before July 1, 2023.","Net loss Q2 2022: $7.6M ($0.19/share) vs $4.6M ($0.12/share) in Q2 2021; OpEx $8.3M, up 41%.","Cash and short-term investments $64.6M at June 30, 2022; funding through at least Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351314,"accession_number":"0001213900-22-045631","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix receives second Complete Response Letter from FDA for DefenCath NDA due to manufacturing deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued second CRL stating DefenCath NDA cannot be approved until deficiencies at CMO and heparin supplier are resolved.","No other deficiencies cited; clinical and labeling review completed per the CRL.","CorMedix entered agreement with Alcami as alternative manufacturer; expects to file NDA supplement around end of Q1 2023.","CMS published conditional NTAP reimbursement, effective if FDA approval by July 1, 2023; duplicate NTAP application planned for October 2022.","Management remains confident of pathway to approval in calendar 2023, with both existing CMO remediation and Alcami transfer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368659,"accession_number":"0001213900-22-025946","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CorMedix: Q1 net loss $7.0M; FDA accepts DefenCath NDA resubmission with 6-mo review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $7.0M ($0.18/shr) vs $7.2M ($0.20/shr) in Q1 2021; operating expenses down 3%.","FDA accepted DefenCath NDA resubmission as complete Class 2 response with 6-month review; inspection planned.","New CEO Joe Todisco officially started May 10; CCO Tom Nusbickel departed by mutual agreement.","Donna Ucci (SVP Global Quality) and Frank Raffaele (VP Supply Chain) hired; Liz Hurlburt promoted.","Winding down European ops, discontinuing Neutrolin distribution to focus on US DefenCath launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-12T23:59:59+00:00|368659"}